AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9552779
Drug: Overall morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall morphine and acetaminophen consumption
Trial: 7925214
Drug: Pancuronium 0.085
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.085 mg kg‐1
Trial: 2973531
Drug: Plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived hepatitis B virus vaccine
Trial: 2973531
Drug: DNA recombinant
RxNorm normalized name: somatropin (recombinant DNA origin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA recombinant hepatitis B virus vaccine
Trial: 791318
Drug: Intramuscular metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular metoclopramide before effervescent aspirin
Trial: 791318
Drug: Effervescent aspirin
RxNorm normalized name: aspirin Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent aspirin alone
Trial: 24584055
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment (ICBT) with systematic exposure to IBS symptoms and related situations
Trial: 24584055
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment without systematic exposure (ICBT‐WE)
Trial: 20178877
Drug: Active acupressure
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active acupressure treatments
Trial: 20178877
Drug: Placebo acupressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo acupressure treatments
Trial: 19031154
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of number and length
Trial: 16553019
Drug: Tiagabine 2
RxNorm normalized name: tiaGABine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 2 mg
Trial: 12735531
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy aimed at ADL activities
Trial: 1906447
Drug: Psyllium preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium preparation (5 ml, 3 times a day for 6 days)
Trial: 6408016
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet (200 kcal) with T3 supplementation (150 micrograms daily)
Trial: 23171524
Drug: Patient-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-oriented treatment decision aid (PORTDA-diab) offered immediately before quarterly practice consultation.
Trial: 17545705
Drug: Vicriviroc 10
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 10 mg twice a day
Trial: 17545705
Drug: Vicriviroc 25
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 25 mg twice a day
Trial: 17545705
Drug: Vicriviroc 50
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 50 mg twice a day
Trial: 12069671
Drug: Early statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early statin therapy (median, 2.0 days after ACS; n = 3952)
Trial: 12069671
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy (n = 8413)
Trial: 2883104
Drug: S 3341
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 3341 (1 and 2 mg)
Trial: 31977878
Drug: Multicomponent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent treatment program for 12 weeks
Trial: 24954843
Drug: Cortisol administration
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol administration (20mg intravenously) before retrieval
Trial: 24954843
Drug: Cortisol administration
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol administration before encoding
Trial: 9762492
Drug: Indirect therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect therapy
Trial: 18821106
Drug: Usual levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual levels of community‐based speech‐and‐language therapy
Trial: 15353155
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) treatment for 1-4 weeks
Trial: 3826809
Drug: Oral phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phenytoin capsules (18 mg/kg)
Trial: 3826809
Drug: Oral phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phenytoin suspension (18 mg/kg)
Trial: 3826809
Drug: Oral phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phenytoin (both forms)
Trial: 30730214
Drug: Free-of-charge subdermal
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-of-charge subdermal etonogestrel implant (SEI)
Trial: 30730214
Drug: Partially paid
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially paid subdermal etonogestrel implant (SEI)
Trial: 30730214
Drug: Free-of-charge and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-of-charge and partially paid subdermal etonogestrel implant (SEI)
Trial: 28349730
Drug: CHO (7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (7.5% CHO; 5 mL · kg‐1 per exercise session; n = 6)
Trial: 28349730
Drug: PLA (0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (0% CHO, taste- and volume-matched solution; n = 6)
Trial: 26717860
Drug: LCPT (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPT (once daily at 0.17 mg/kg/d)
Trial: 26717860
Drug: IR-Tac (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR-Tac (twice daily at 0.1 mg/kg/d)
Trial: 20018274
Drug: Beta-blockers (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (Group 2)
Trial: 20018274
Drug: Anxiolytics (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytics (Group 3)
Trial: 15102874
Drug: 1.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/day FTY720
Trial: 15102874
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day FTY720
Trial: 12226034
Drug: IV preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV preparation (80 mg in 2 mL vial diluted with 2 mL saline containing preservatives)
Trial: 12226034
Drug: Preservative-free preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free preparation (300 mg in 5 mL solution)
Trial: 12226034
Drug: IV preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV preparation
Trial: 12226034
Drug: Preservative-free preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free preparation
Trial: 9839330
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration before hepatic DSA
Trial: 8205581
Drug: Rembrandt Lighten
RxNorm normalized name: Rembrandt
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rembrandt Lighten Bleaching Gel
Trial: 2732125
Drug: Oral rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral rifampicin 900 mg/day plus oral doxycycline 200 mg/day for 45 days (Regimen A)
Trial: 2732125
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 200 mg/day for 45 days plus im streptomycin 1 g/day for 21 days (Regimen B)
Trial: 2732125
Drug: WHO regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO regimen combining oral tetracycline 2 g/day for 21 days plus im streptomycin 1 g/day for 14 days (Regimen C)
Trial: 26159140
Drug: Silver-Care-Robot Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver-Care-Robot Program (conducted twice a week for 5 weeks)
Trial: 21600084
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of compound azintamid (2 tablets 3 times a day) and domperidone (10 mg 3 times a day) for 4 weeks
Trial: 21600084
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of compound azintamid and domperidone
Trial: 21600084
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg 3 times a day) for 4 weeks
Trial: 10326889
Drug: LNG-containing oral
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-containing oral contraceptive minipills (30 mirog)
Trial: 1778327
Drug: JNIH-7 (mono-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNIH-7 (mono-component vaccine)
Trial: 1778327
Drug: JNIH-6 (two-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNIH-6 (two-component vaccine)
Trial: 7095559
Drug: prednisolone/azathioprine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone/azathioprine therapy
Trial: 31914940
Drug: Rifampin, 600
RxNorm normalized name: Rifampin, 600 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin, 600 mg daily for 6 weeks
Trial: 30935657
Drug: Ocriplasmin (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin (0.125 mg intravitreal injection)
Trial: 28881220
Drug: Daily life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily life EF behavior
Trial: 17321928
Drug: Ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.15 mg/kg IV
Trial: 15138439
Drug: Methamphetamine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (0.15 mg/kg)
Trial: 2438923
Drug: Pirmenol hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirmenol hydrochloride (200 to 400 mg daily)
Trial: 28539539
Drug: Bococizumab 50
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 50 mg
Trial: 28539539
Drug: Bococizumab 100
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 100 mg
Trial: 28539539
Drug: Bococizumab 150
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 150 mg
Trial: 23438223
Drug: Taste-matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taste-matched placebo (PLB) solution
Trial: 19188925
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin (5 pmol kg(‐1) min(‐1))
Trial: 16507585
Drug: Fontolizumab 4
RxNorm normalized name: Fontolizumab
DrugBank: Fontolizumab (DB05111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fontolizumab 4 mg/kg
Trial: 16507585
Drug: Fontolizumab 10
RxNorm normalized name: Fontolizumab
DrugBank: Fontolizumab (DB05111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fontolizumab 10 mg/kg
Trial: 15640628
Drug: Afelimomab 1
RxNorm normalized name: afelimomab
DrugBank: Afelimomab (DB04956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afelimomab 1 mg/kg for 3 days
Trial: 8298071
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride (12 mg dose) administered after a standardized meal
Trial: 8298071
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride (12 mg dose) administered after fasting for 12 hours
Trial: 3106096
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg for 5 days
Trial: 3106096
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg intravenous bolus followed by 1.6 mg/hour for 9 hours)
Trial: 2661789
Drug: MBDL regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBDL regimen (metoclopramide 8 mg/kg, benztropine 0.04 mg/kg, dexamethasone 0.7 mg/kg, lorazepam 0.1 mg/kg)
Trial: 2661789
Drug: Chlorpromazine (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (3.3 mg/kg in four doses over 24 hours)
Trial: 31292845
Drug: Tongxiening Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxiening Granules (TXNG) 5 g per time combined with pinaverium bromide Tablet simulator (50 mg per time), 3 times per day for 6 weeks
Trial: 31292845
Drug: TXNG simulator
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXNG simulator (5 g per time) combined with pinaverium bromide Tablets (50 mg per time), 3 times per day for 6 weeks
Trial: 25070686
Drug: (177)Lu-EDTMP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (177)Lu-EDTMP at a dose of 1,295 MBq (group A)
Trial: 25070686
Drug: (177)Lu-EDTMP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (177)Lu-EDTMP at a dose of 2,590 MBq (group B)
Trial: 7984592
Drug: Detoxication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detoxication therapy at the start of combined treatment
Trial: 7984592
Drug: Detoxication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detoxication therapy
Trial: 25186820
Drug: Propofol-based total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based total intravenous anaesthesia
Trial: 9974425
Drug: HRT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (2 mg estradiol valerate from day 1 to 21 and 1 mg cyproterone acetate from day 12 to 21)
Trial: 9974425
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg/d calcium lactate)
Trial: 30012387
Drug: Horticultural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural therapy program (twice/week for 12 sessions)
Trial: 22030724
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (group S): 30 mL of mepivacaine 1.5%
Trial: 22030724
Drug: Double injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double injection (group D): 15 mL of mepivacaine 1.5% at the junction of the subclavian artery and the first rib, followed by 15 mL at the lateral aspect of the brachial plexus
Trial: 22030724
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (group S)
Trial: 22030724
Drug: Double injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double injection (group D)
Trial: 19776178
Drug: S-(-)equol administered
RxNorm normalized name: S-equol
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(-)equol administered as SE5-OH tablets (10 mg)
Trial: 19776178
Drug: S-(-)equol administered
RxNorm normalized name: S-equol
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(-)equol administered as SE5-OH tablets (30 mg)
Trial: 19776178
Drug: S-(-)equol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(-)equol (both doses)
Trial: 9440721
Drug: Interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2a maintenance, 3 million U three times weekly for 1 year
Trial: 2570732
Drug: Aspirin 900
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 900 mg b.i.d. for 48 h
Trial: 2570732
Drug: Famotidine 2
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 2 mg b.i.d.
Trial: 31336766
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no topical antiglaucoma medications)
Trial: 15942709
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lafutidine
Trial: 31891605
Drug: D2/D3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2/D3 receptor agonist pramipexole
Trial: 23721411
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of gentamicin in combination with metronidazole
Trial: 23721411
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of gentamicin in combination with metronidazole
Trial: 17926989
Drug: WF10 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WF10 (0.5 mL/kg body weight/day for five consecutive days, repeated every 3 weeks)
Trial: 8707752
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg valaciclovir
Trial: 8707752
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL Maalox 65 min after valaciclovir
Trial: 8707752
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL Maalox 30 min before valaciclovir
Trial: 1602388
Drug: i.v. cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. cocaine hydrochloride (0, 16 and 32 mg)
Trial: 1602388
Drug: smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: smoked cocaine base (0, 25 and 50 mg)
Trial: 1602388
Drug: smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: smoked cocaine base (50 mg)
Trial: 29912422
Drug: Guided de-escalation
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided de-escalation regimen (1 week prasugrel followed by 1 week clopidogrel and guided maintenance therapy)
Trial: 22052104
Drug: Icodextrin 4%
RxNorm normalized name: ICODEXTRIN 4% IRRG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icodextrin 4% solution administered intraperitoneally
Trial: 22052104
Drug: Icodextrin 4%
RxNorm normalized name: ICODEXTRIN 4% IRRG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icodextrin 4% solution
Trial: 19605605
Drug: Single patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single patient trials (SPTs) for commonly employed treatments in palliative care, specific drugs not mentioned.
Trial: 10150322
Drug: Ampicillin/sulbactam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (2 g/1 g)
Trial: 1967947
Drug: Vecuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.01 mg kg‐1 as a priming dose followed by 0.1 mg kg‐1 intubation dose
Trial: 1967947
Drug: No priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No priming dose of vecuronium
Trial: 31757262
Drug: 8 mg/day
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/day galantamine
Trial: 31757262
Drug: 16 mg/day
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/day galantamine
Trial: 26138419
Drug: miR‐21‐5p overexpression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miR‐21‐5p overexpression group (adenovirus+0.5 mmol/L H2O2)
Trial: 26138419
Drug: H2O2 challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2O2 challenge group (0.5 mmol/L H2O2)
Trial: 26138419
Drug: miR‐21‐5p negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miR‐21‐5p negative transfection group (adenovirus void+0.5 mmol/L H2O2)
Trial: 21444867
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (NAT)
Trial: 18667139
Drug: Insulin initiation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin initiation in patients with T2DM
Trial: 15852734
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or chemoradiation followed by surgery
Trial: 11226106
Drug: LR Before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR Before group (12 mL/kg of LR solution within 20 min before spinal anesthesia)
Trial: 11226106
Drug: LR After
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR After group (12 mL/kg of LR solution within 20 min starting immediately after spinal anesthesia)
Trial: 11226106
Drug: No Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Infusion group (no LR solution given)